MELBOURNE, Australia and INDIANAPOLIS, Jan. 16, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), a Phase 3 trial to  evaluate the use of Telix’s commercial PSMA-PET^[1] imaging agents, Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) and Gozellix® (kit for the preparation of gallium Ga 68 gozetotide injection) in the initial prostate cancer diagnosis setting. The dose was administered under the supervision of Dr. Brian Mazzarella at Urology Austin and supplied by RLS Radiopharmacies.

BiPASS™ is the first study designed to gain marketing authorization for ⁶⁸Ga-PSMA-PET^[2] imaging in the pre-biopsy setting. The prospective, open-label Phase 3 trial will enroll 250 patients across sites in the U.S. and Australia. The study aims to determine whether combining MRI^[3] with Illuccix/Gozellix ⁶⁸Ga-PSMA-11 PET can improve diagnostic accuracy and reduce unnecessary biopsies compared to current standard practice. Men with elevated PSA^[4] often proceed from an inconclusive MRI to template prostate biopsy. This procedure is stressful and unpleasant, can lead to complications^[5] and frequently proves to be of no benefit to the patient^[6].

In the U.S., more than one million prostate biopsies are performed annually, yet up to 75% are negative^[6], and one in four patients declines the physician recommendation of receiving a biopsy^[7]. The objective of BiPASS™ is to demonstrate improved lesion detection and patient stratification by integrating non-invasive molecular Illuccix/Gozellix ⁶⁸Ga-PSMA-11 PET imaging early in the diagnostic pathway, to enable biopsy de-escalation or, alternatively, greater biopsy precision when administered.

If the BiPASS™ study achieves its primary objectives, it could lead to a reduction in unnecessary biopsies, improved patient experience, and a significant expansion of access to precision imaging for patients with suspected prostate cancer, potentially increasing the use of ⁶⁸Ga-PSMA-11 PET in a large new patient population.

Dr. Mazzarella, Vice President of Research for Urology America, said, “We’re excited to participate in the BiPASS trial at Urology Austin, which brings together promising technologies and emerging trends in patient care.  If BiPASS is successful in meeting its primary endpoint, it could eliminate the need for biopsy—reducing risks, side effects, and costs—and improve decision-making for providers and patients.”

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, added, “Illuccix and Gozellix are already transforming how clinicians treat and manage prostate cancer. By initiating this trial, we are reinforcing Telix’s commitment to patient centricity, clinical innovation, and industry leadership—with the goal of eliminating invasive biopsy.”

About BiPASS™

BiPASS™ (ClinicalTrials.gov ID: NCT07052214) leverages promising clinical findings from the PRIMARY^[8] and PRIMARY2^[9] studies, which demonstrated that MRI combined with ⁶⁸Ga-PSMA-11 PET can better define or rule out prostate cancer and guide active surveillance before invasive biopsy. Professor Louise Emmett, Principal Investigator for PRIMARY, serves on the BiPASS™ Steering Committee and as an Investigator on the study.

About Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection)

Illuccix, after radiolabeling with ⁶⁸Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive therapy, those with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level, and for selection of patients who are indicated for PSMA-directed therapy as described in the prescribing information of the therapeutic products.

About Gozellix® (kit for the preparation of gallium Ga 68 gozetotide injection)

Gozellix, after radiolabeling with ⁶⁸Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive therapy, and those with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix, Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix has been approved by the U.S. FDA^[10]. Illuccix and Gozellix have not received regulatory approval for initial diagnosis of prostate cancer in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.)  

Annie Kasparian 
Telix Pharmaceuticals Limited 
Director Investor Relations and Corporate Communications 
Email: annie.kasparian@telixpharma.com 

Media Contact

Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

Source

Ships Worldwide January 16: The Upgraded Tactile Fabric and dynamic support mark the start of a restorative work era.

HONG KONG, Jan. 17, 2026 /PRNewswire/ — Following immense anticipation, LiberNovo, the pioneer of dynamic ergonomic seating, today officially announced the immediate availability of its new Moss Green variant for the LiberNovo Omni chair. The new model, which builds on the success of Midnight Black and Space Grey, is now available globally, with launch promotions for US customers.

This launch responds directly to growing user demand for seating that blends world-class ergonomic engineering with a warm, natural aesthetic. The Moss Green edition is ready for immediate order and marks a key milestone in the company’s 2026 global expansion, allowing users to invest in both their physical support and their home environment.

Engineered for Presence

The Moss Green LiberNovo Omni provides a comprehensive ergonomic solution for today’s intensive creators. It serves programmers and remote workers who demand sustained focus, alongside creatives and gamers who require seamless, adaptive support during rapid task switching, all guided by the principle: Support by Motion, Defined by Comfort.

Color & Comfort Refinement

Inspired by forest moss, the Moss Green hue blends deep green with gentle warmth, creating an understated yet vibrant tone that immediately conveys emotional comfort. This natural aesthetic subtly integrates a sense of nature into any workspace, making the environment more calming and restorative.

In addition to the new color, the Moss Green design debuts a significant material refinement: a short-pile surface that is exceptionally soft and delicate, yet remains breathable and skin-friendly for superior comfort. Crucially, this luxurious feel is matched by industry-leading durability:

• Abrasion resistance: Tested to withstand more than 50,000 wear cycles
• Pilling resistance: Grade 4 after 5,000 cycles
• Color fastness (dry): Grade 4

Ergonomic Intelligence for Every Task

The Moss Green edition retains the LiberNovo Omni’s core dynamic ergonomic system, positioning it as the world’s first chair to respond dynamically to the body’s natural movements. This is critical for users focused on health and or managing body pain.

• Dynamic Support System: Instantly adjusts to posture shifts, maintaining continuous lumbar alignment
• Bionic FlexFit Backrest: Utilizes 16 pivot points and 8 adaptive panels for comprehensive, full-back support
• Four Recline Modes: Ranging from 105° for focused work to 160° for deep spinal decompression with OmniStretch, ideal for recovery during long sessions

Limited-Time Discounts & Bundles

To celebrate the launch, customers can access limited-time discounts across all bundles and configurations, offering savings of up to 32% off MSRP.

North America Exclusive Gift Package: The first 1,000 U.S. orders over $800 and the first 500 Canada orders over CA$1,200 will each receive an exclusive three-piece gift set, including a silk eye mask, an eco tote bag, and a supportive footrest cushion.

Specific North American Availability

Please note the specific timing for the Official Sale period:

• United States (PST/UTC-8):
  • Official Sale begins on January 16th at 18:00 (PST) and runs until March 16th at 18:00 (PST).
• Canada (EST):
  • Official Sale begins on January 17th at 01:00 (EST) and runs until March 17th at 01:00 (EST).

Pricing and How to Order

The LiberNovo Omni Moss Green Basic Bundle starts at $829 USD (MSRP: $1,099), reflecting the special launch discounts. All orders are fulfilled via fast, warehouse-direct shipping.

Begin your restorative work journey and secure your chair today by visiting:

https://libernovo.com/

Source

The National University Centre for Digestive Health heralds a new era of care through quicker cross-referrals to surgical specialties, strengthened community partnerships and patient-friendly treatment delivery

SINGAPORE, Jan. 16, 2026 /PRNewswire/ — Digestive health is central to overall well-being, influencing nutrition, immunity, and quality of life. Yet common conditions, such as ulcers, liver disease, and colorectal disorders, often go undetected until they lead to serious complications. To address this, the National University Hospital (NUH) has officially opened the National University Centre for Digestive Health (NUCD), a facility dedicated to early detection, advanced treatment, and seamless patient care for digestive diseases.

Since its concept launch in 2024, NUCD has focused on consolidating NUH’s digestive health services under one roof to provide greater convenience for patients. Its reach extends beyond NUH, serving as a referral hub for complex cases from other hospitals within the National University Health System, including Ng Teng Fong General Hospital and Alexandra Hospital, ensuring patients receive specialised care when needed.

With its official opening, the Centre is strengthening the entire care pathway by accelerating access from initial digestive consultation to surgical expertise in Upper Gastrointestinal, Hepatobiliary and Pancreatic, and Colorectal, so patients can see the right specialists on the same day. This streamlined approach reduces waiting times, minimises repeated visits, and enables faster treatment decisions for better outcomes.

Strengthening prevention: From community collaborations to clinical excellence

NUCD has contributed significantly to the clinical validation and implementation of the Fibrosis-4 (FIB-4) score and fibroscan to screen for liver fibrosis, or scarring of the liver, in high-risk patients with fatty liver and other chronic liver diseases^[1]. Since September 2022, a chronic liver disease screening programme for high-risk individuals has been launched in partnership with National University Polyclinics and General Practitioners (GP) clinics. Through consultations and routine health assessments done at these clinics, asymptomatic individuals identified as potentially high-risk are referred to NUCD for comprehensive screening. To date, the Centre has screened more than 12,000 high-risk patients, facilitating earlier detection and interventions. With continuing medical education and engagement, NUCD continues to expand this network to enhance preventive care for liver health.

Another key focus of the Centre is improving the detection of colorectal cancer, often called a ‘silent killer’ because symptoms usually appear only in later stages. According to the Singapore Cancer Registry Annual Report 2022^[2], colorectal cancer is the second most common cancer and the second leading cause of cancer-related deaths locally. To tackle this, the Centre is improving colonoscopy quality by increasing the Adenoma Detection Rate (ADR), a measure of how often doctors detect and remove precancerous polyps during the procedure.

Studies^[3] show that every 1 per cent increase in ADR lowers colorectal cancer risk by 3 per cent, making these improvements a vital step in prevention. Put simply, a higher ADR means that more polyps are removed early, reducing cancer risk. New initiatives such as AI-enabled and image-enhanced colonoscopy, an automated ADR calculation system, and a dashboard displaying critical quality indicators for endoscopists have helped boost ADR at NUCD from 33.5 per cent in 2022 to 42.4 per cent in 2025, well above the American Society for Gastrointestinal Endoscopy guideline of at least 25 per cent^[4].

Making IBD care more convenient and precise

Established in 2016, the Inflammatory Bowel Disease (IBD) Centre of Excellence is now a cornerstone of NUCD, delivering advanced care across all ages – from paediatric to adult patients. Among its key innovations is the home administration of intravenous biologics, reducing the need for frequent hospital visits and improving convenience.

Others include point-of-care intestinal ultrasound, which enables real-time, non-invasive assessment during clinic consultations, and a translational precision medicine programme that personalises treatment and provides access to clinical trials and novel therapies, such as faecal microbiota transplantation. The IBD Centre of Excellence also aims to play a leading role in regional education, having hosted IBD training programmes for over 100 healthcare professionals from ASEAN countries in the past five years.

“The launch of NUCD marks a significant step forward in how we care for patients with digestive conditions,” said Adj A/Prof Lee Guan Huei, Centre Director, National University Centre for Digestive Health. “By bringing together advanced diagnostics, specialist expertise, and cutting-edge technology, we aim to deliver care that is faster, more precise, and patient-focused. At the same time, we are driving research into new detection methods and innovative therapies, such as blood-based diagnostic tools that reduce the need for invasive procedures while maintaining accuracy. Our goal is simple – to detect problems early, treat them well, and help our patients live healthier lives.” Adj A/Prof Lee is also Head and Senior Consultant, Division of Gastroenterology and Hepatology, Department of Medicine, NUH.

About the National University Hospital (NUH)

­­The National University Hospital (NUH) is Singapore’s leading university hospital. While the hospital at Kent Ridge first received its patients on 24 June 1985, our legacy started from 1905, the date of the founding of what is today the NUS Yong Loo Lin School of Medicine. NUH is the principal teaching hospital of the medical school.

Our unique identity as a university hospital is a key attraction for healthcare professionals who aspire to do more than practise tertiary medical care. We offer an environment where research and teaching are an integral part of medicine, and continue to shape medicine and transform care for the community we care for.

We are an academic medical centre with over 1,200 beds, serving more than one million patients a year with over 50 medical, surgical and dental specialties. NUH is the only public and not-for-profit hospital in Singapore to provide trusted care for adults, women and children under one roof, including the only paediatric kidney and liver transplant programme in the country.

The NUH is a key member of the National University Health System (NUHS), one of three public healthcare clusters in Singapore. For more information, visit www.nuh.com.sg

Follow us on

Facebook | Instagram | LinkedIn | TikTok | YouTube

Source

Major Retail Event for Greater Bay Area Residents

Following “Southbound Travel for Guangdong Vehicles” Scheme

HONG KONG, Jan. 16, 2026 /PRNewswire/ — Organized by Exhibition Group, the “Grand Sale Bazaar 2026” opens today and runs until January 19 (Friday to Monday) at Hall 5,7,9 of AsiaWorld-Expo, marking a new annual mega event combining shopping and entertainment in Hong Kong. The “Grand Sale Bazaar 2026” has become one of the major retail events for Greater Bay Area residents following the implementation of the “Southbound Travel for Guangdong Vehicles” scheme, poised to become a new hotspot for mainland visitors shopping in Hong Kong, further promoting economic integration and consumer market development between the two regions.

The opening ceremony was officiated by Dr Bernard Chan, Under Secretary for Commerce and Economic Development of the Government of the Hong Kong Special Administrative Region; Ms. Jackie Ng, Deputy Chairman of Federation of Hong Kong Industries; Mr. Dennis Wong, General Manager, Business Development of AsiaWorld-Expo Management Limited; Mr. Sam Hui, Council Member and Past Chairman of The Chamber of HK Computer Industry; Mr. Allen Kwong, Chairman of Hong Kong Furniture and Decoration Trade Association (HKFDA); Mr. John Wong, Chairman of Federation of Hong Kong Brands; Ms. May Leung, Chairman of The Professional Validation Council of Hong Kong Industries; Ms. Emily Cheung, Director of MameShare; Ms. Christine Lo, Director of Business Development, Marketing & Branding of The Payment Cards Group Limited; Ms. Teresa Ho, Senior Business Development & Marketing Manager of LBuy; Mr. Andy Wong, Founder of HK Singer Channel and Mr. Carl Wong, Chairman of the Exhibition Group.

The “Grand Sale Bazaar 2026” brings together local and international fashion apparel, beauty products, home appliances, jewelry, outdoor sports equipment, baby products, health foods, and trendy merchandise, creating an ideal shopping and leisure destination for consumers. The Bazaar has attracted over 400 booths with merchandise valued at approximately HK$100 million, offering discounts of up to 90% off original prices, providing an excellent opportunity for citizens to purchase New Year goods at exceptional value. The venue features up to 350 DGG by LBuy gachapon machines and various entertainment programs, including the “Retro Hits Concert,” bringing citizens a consumer extravaganza that combines exceptional warehouse sales and shopping entertainment.

Exhibition Group Chairman Carl Wong stated: “Following the implementation of the “Southbound Travel for Guangdong Vehicles” scheme, we hope to establish the “Grand Sale Bazaar 2026″ as a shopping event that Hong Kong and Greater Bay Area consumers look forward to every year. We have strategically chosen AsiaWorld-Expo, taking full advantage of its proximity to the Hong Kong-Zhuhai-Macao Bridge, making it convenient for mainland visitors to drive here. We hope that through this annual event, we can promote consumer market exchange in the Greater Bay Area and inject new momentum into Hong Kong’s retail market.”

Eight Major Themed Warehouse Sale Zones

The inaugural event features eight major themed warehouse sale zones, covering fashion apparel, home appliances, trendy merchandise, personal care, health foods, jewelry and watches, baby products, and outdoor sports—all popular categories among citizens. This aims to provide consumers with different needs a one-stop warehouse shopping experience. Major brands offer unprecedented warehouse sale discounts, with some items discounted up to 90% off original prices, allowing citizens to snap up their favorites at exceptional value and purchase New Year goods early.

I.T MEGA Winter Sale – Largest-Ever Warehouse Sale

Key exhibitor I.T (Booth 5-C19) occupies over 6,600 square feet, featuring over 8,000 selected trendy apparel and accessories from Europe, America, Japan, and Korea, with discounts of up to 90% off storewide. Citizens can enjoy multiple offers: an extra 10% off the total bill when purchasing 2 designated items, or an extra 20% off the total bill when purchasing 4 designated items; spend a net amount of $800 and receive an additional $100 off the total bill. Limited lucky bags are available daily at just HK$299 (valued at over HK$1,000), available in limited quantities on a first-come, first-served basis while stocks last.

DGG by LBuy Gachapon Bazaar – 350 Gachapon Machines Adding Surprises

DGG by LBuy Gachapon Bazaar is participating in this event for the first time, featuring 350 gachapon machines offering a variety of surprise products and premium items suitable for all ages. Providing over 200 gachapon options in total, adding shopping surprises for families and young people.

Unmissable Warehouse Sale Offers

Bringing together warehouse sale offers from numerous well-known brands, the venue offers a large selection of products at half-price and 90% off exceptional values. This covers multiple categories including home electronics and audio, furniture and bedding, personal care, and food and beverages, allowing citizens to shop for everything they need in one go. The home appliance zone offers kitchen appliances, smart TVs, and home audio systems and other practical products; the home living area features quality furniture, memory pillows, and branded mattresses, with some items reduced by tens of thousands of dollars; beauty and skincare essences, imported wines, and specialty fruit liqueurs are also available at 10% off prices. Many unmissable offers are available in limited quantities while stocks last, allowing citizens to purchase their favorite items at the best prices and enjoy New Year shopping pleasures.

Shopping and Entertainment Combined – Retro Hits Concert Relives the Classics

In addition to warehouse shopping, the inaugural Bazaar has also arranged diverse stage programs and on-site experiences, including the “Retro Hits Concert,” featuring Bill Ng, Edward Pao, Willie, Li Lung Kay, and other renowned singers/guests performing classic songs live, reliving the good old days and combining nostalgic and modern elements to bring unforgettable musical experiences to audiences of all ages. Citizens can grab warehouse sale bargains while enjoying spectacular performances, experiencing the dual pleasure of shopping and entertainment.

The inaugural Bazaar combines exceptional warehouse sales, shopping, entertainment, and family experiences, allowing citizens to purchase New Year goods in a relaxed manner all at once and experience the festive atmosphere of the New Year early, ensuring that every visitor has an enjoyable and rewarding experience.

Grand Sale Bazaar 2026

About Exhibition Group

Exhibition Group is one of Hong Kong’s renowned exhibition companies. Our core team has been assembled since 2003, bringing together a group of innovative, experienced, and professional exhibition talents. As a leading event management company, specializing in the planning and operation of world-class public exhibitions, conferences, and trade fairs, covering a wide range of industries. With years of industry experience, we are committed to the development of exhibition and marketing businesses, gaining a prestigious reputation within the exhibition industry.

Our company organizes a variety of themed exhibitions and marketing projects, which not only receive substantial support from the business community and exhibitors but also effectively attract a large number of public participants. Each event has garnered rave reviews, resulting in a win-win situation for exhibitors in both product promotion and sales. Notable exhibitions include the Pet Show, In-Home Expo, Premium Pet Supplies Expo, Hong Kong Cat Expo, Hong Kong Holiday & Travel Expo, Extracurricular Activities Festival cum Teaching Materials and Supplies Expo, and Hong Kong Outdoor & Sports Expo, among others. In recent years, our company has been honored with several awards, including the “Outstanding Award for Pandemic Resilience,” “ESG Commendation Awards,” and “Innovative Exhibition Planning,” recognizing our business development achievements across various sectors.

This press release is distributed by Market Hubs Holdings Limited.

Source